None. cydy false 0001175680 --05-31 0001175680 2021-11-24 2021-11-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

November 24, 2021

 

 

CytoDyn Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-49908   83-1887078

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1111 Main Street, Suite 660

Vancouver, Washington 98660

(Address of principal executive offices, including zip code)

(360) 980-8524

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

None   None   None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Explanatory Note

This Current Report on Form 8-K is being filed by CytoDyn Inc. (“CytoDyn” or the “Company”) in order to disclose the final voting results for the Company’s annual meeting of stockholders (the “Annual Meeting”) held on November 24, 2021 as provided by Michael Barbera of First Coast Results, the independent Inspector of Election for the Annual Meeting (the “Inspector of Election”).

 

ITEM 5.03    

Amendments to the Articles of Incorporation or Bylaws; Change in Fiscal Year.

As described in more detail under Item 5.07 of this Form 8-K, at the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “Charter”) to increase the total number of authorized shares of common stock from 800,000,000 to 1,000,000,000. The material terms of the Amendment are summarized under the heading “Proposal No. 4 — Approval Of Amendment To Certificate Of Incorporation” in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on October 14, 2021 (the “Proxy Statement”).

The Amendment became effective upon the filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on November 24, 2021. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

ITEM 5.07    

Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the stockholders of the Company voted on the following proposals, each of which is more fully described in the Proxy Statement:

 

  1.

To elect six (6) directors to serve on the Board of Directors until the 2022 annual meeting of stockholders, until their successors are duly elected and qualified or until their earlier death, resignation or removal;

 

  2.

To ratify, on an advisory (non-binding) basis, the selection of Warren Averett, LLC as our independent registered public accounting firm for the fiscal year ending May 31, 2022;

 

  3.

To approve, on an advisory (non-binding) basis, our named executive officer compensation; and

 

  4.

To approve a proposal to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 800,000,000 to 1,000,000,000.

On November 24, 2021, the Inspector of Election issued its final report which certified the final voting results for the Annual Meeting. Set forth below are the final voting results as provided by the Inspector of Election.

Each stockholder of record is entitled to one vote per share of common stock. On September 1, 2021, the record date for the Annual Meeting (the “Record Date”), there were 651,746,095 votes underlying the issued and outstanding shares of common stock. Present at the Annual Meeting in person or by proxy were holders of common stock representing an aggregate of 491,052,892 votes, or 75.34% of the voting power underlying the issued and outstanding shares entitled to vote at the Annual Meeting as of the Record Date, constituting a quorum. Of the shares present at the Annual Meeting, there were 99,404,642 shares of common stock that were not voted by stockholders with respect to proposals 1 and 3. Since these proposals are non-discretionary proposals under the NYSE rules, brokers could not vote such shares with respect to these proposals.

 

1.

Election of Directors

 

Company Nominee   For   Withheld

Scott A. Kelly, M.D.

  308,235,150   83,413,100

Nader Z. Pourhassan, Ph.D.

  286,413,228   105,235,022

Jordan G. Naydenov

  266,091,088   125,557,162

Lishomwa C. Ndhlovu, M.D., Ph.D.

  317,928,888   73,719,362

Harish Seethamraju, M.D.

  319,659,131   71,989,119

Tanya Durkee Urbach

  316,300,797   75,347,453


The stockholders voted to elect each of the Company’s director nominees to serve until the Company’s 2022 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.

 

2.

Ratification of Appointment of Independent Registered Public Accounting Firm

 

For

 

Against

   

Abstentions

 
413,974,584     61,104,389       15,973,919  

The stockholders voted to ratify the selection of Warren Averett, LLC as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2022.

 

3.

Advisory Vote on Compensation of Named Executive Officers

 

For

 

Against

   

Abstentions

 
229,935,096     141,470,338       20,242,816  

The stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers.

 

4.

Approval of Amendment to the Certificate of Incorporation

 

For

 

Against

   

Abstentions

 
378,450,289     96,149,095       16,453,508  

The stockholders voted to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 800,000,000 to 1,000,000,000.

No other matters were properly presented for consideration or stockholder action at the Annual Meeting.

 

Item 9.01.    

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

  

Description

3.1    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of CytoDyn Inc., effective November 24, 2021.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CYTODYN INC.
Date: November 24, 2021      
    By:  

/s/ Antonio Migliarese

     

Antonio Migliarese

Chief Financial Officer

CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more CytoDyn (QB) Charts.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more CytoDyn (QB) Charts.